JP2020132588A - 血中pcsk9濃度上昇抑制用組成物 - Google Patents
血中pcsk9濃度上昇抑制用組成物 Download PDFInfo
- Publication number
- JP2020132588A JP2020132588A JP2019029686A JP2019029686A JP2020132588A JP 2020132588 A JP2020132588 A JP 2020132588A JP 2019029686 A JP2019029686 A JP 2019029686A JP 2019029686 A JP2019029686 A JP 2019029686A JP 2020132588 A JP2020132588 A JP 2020132588A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- psicose
- pcsk9
- concentration
- increase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 51
- 210000004369 blood Anatomy 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims abstract description 47
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 claims abstract description 40
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000037396 body weight Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 14
- 241000699800 Cricetinae Species 0.000 description 13
- 230000037406 food intake Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 102000053786 human PCSK9 Human genes 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 102000000853 LDL receptors Human genes 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100135853 Rattus norvegicus Pcsk9 gene Proteins 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 235000010746 mayonnaise Nutrition 0.000 description 2
- 239000008268 mayonnaise Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 101100135848 Mus musculus Pcsk9 gene Proteins 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
[1]D−プシコースを有効成分とする血中PCSK9濃度上昇抑制用組成物。
[2]1日に体重1kg当たり0.1g〜0.5gのD−プシコースを摂取させるための上記[1]記載の組成物。
[3]1日に体重1kg当たり0.1g〜0.5gのD−プシコースを少なくとも28日継続して摂取させるための上記[1]記載の組成物。
[4]D−プシコースを有効成分とする血中PCSK9濃度上昇抑制剤。
[5]1日に体重1kg当たり0.1g〜0.5gのD−プシコースを摂取させるための上記[4]記載の剤。
[6]1日に体重1kg当たり0.1g〜0.5gのD−プシコースを少なくとも28日継続して摂取させるための上記[4]記載の剤。
[7]1日に体重1kg当たり0.1g〜0.5gのD−プシコースを少なくとも28日継続して摂取させる、PCSK9の血中濃度上昇を抑制する方法。
D−プシコース摂取によるハムスターの血中のPCSK9濃度に対する影響を確認した。実験動物は5週齢の雄のGolden Syrian hamster(以下、ハムスターという。)16匹及び4週齢のハムスター16匹とした。まず、5週齢のハムスター16匹を1週間予備飼育した後、コントロール摂取群及び3%D−プシコース摂取群の2群(1群あたり8匹)に分け、表1の組成に従った通常の実験飼料(以下、通常食という。)と水を自由摂取として8週間飼育した。その後、各ハムスターから採血を行った。次に4週齢のハムスター16匹を1週間予備飼育した後、表1の組成に従った高脂肪の実験飼料(以下、高脂肪食という。)と水を4週間自由摂食させ、肥満を誘導した。
上述のハムスター(32匹)の血中のPCSK9濃度を、市販キット(サイクレックス社製「CircuLex Mouse/Rat PCSK9 ELISA Kit」)を用いて測定した。各個体の血中PCSK9濃度を群ごとに平均した値を表2に示す。
次に、D−プシコース継続摂取によるヒトの血中のPCSK9濃度に対する影響を確認した。被験者は20歳以上70歳未満の男性であり、高コレステロール血症の未治療者(120mg/dl≦空腹時LDL−C<160mg/dl:7名)及びLDLコレステロール値の上昇が予想される糖尿病境界型の未治療者(110mg/dl≦空腹時血糖値<126mg/dl、又は6.2<HbA1c(NGSP)<6.5:7名)とした。
上述の全被験者(14名)の血中PCSK9濃度を市販キット(サイクレックス社製「CircuLex Human PCSK9 ELISA Kit」)を用いて測定した。各個体の血中PCSK9濃度の全被験者の平均値及び標準偏差を表3及び図2に示す。
Claims (7)
- D−プシコースを有効成分とする血中PCSK9濃度上昇抑制用組成物。
- 1日に体重1kg当たり0.1g〜0.5gのD−プシコースを摂取させるための請求項1記載の組成物。
- 1日に体重1kg当たり0.1g〜0.5gのD−プシコースを少なくとも28日継続して摂取させるための請求項1記載の組成物。
- D−プシコースを有効成分とする血中PCSK9濃度上昇抑制剤。
- 1日に体重1kg当たり0.1g〜0.5gのD−プシコースを摂取させるための請求項4記載の剤。
- 1日に体重1kg当たり0.1g〜0.5gのD−プシコースを少なくとも28日継続して摂取させるための請求項4記載の剤。
- 1日に体重1kg当たり0.1g〜0.5gのD−プシコースを少なくとも28日継続して摂取させる、PCSK9の血中濃度上昇を抑制する方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019029686A JP2020132588A (ja) | 2019-02-21 | 2019-02-21 | 血中pcsk9濃度上昇抑制用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019029686A JP2020132588A (ja) | 2019-02-21 | 2019-02-21 | 血中pcsk9濃度上昇抑制用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020132588A true JP2020132588A (ja) | 2020-08-31 |
Family
ID=72277700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019029686A Pending JP2020132588A (ja) | 2019-02-21 | 2019-02-21 | 血中pcsk9濃度上昇抑制用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2020132588A (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018530600A (ja) * | 2015-09-01 | 2018-10-18 | シージェイ チェルジェダン コーポレイション | D−プシコースを利用した脂質の吸収抑制および/または排出促進方法 |
-
2019
- 2019-02-21 JP JP2019029686A patent/JP2020132588A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018530600A (ja) * | 2015-09-01 | 2018-10-18 | シージェイ チェルジェダン コーポレイション | D−プシコースを利用した脂質の吸収抑制および/または排出促進方法 |
Non-Patent Citations (4)
Title |
---|
EXPERIMENTAL CELL RESEARCH, vol. 366, JPN6022048422, 2018, pages 152 - 160, ISSN: 0005011426 * |
J SCI FOOD AGRIC, vol. 98, JPN6022048423, 2017, pages 2020 - 2026, ISSN: 0005011424 * |
JOURNAL OF LIPID RESEARCH, vol. 44, JPN6022048421, 2003, pages 2109 - 2119, ISSN: 0005011425 * |
PNAS, vol. 102, no. 15, JPN6022048425, 2005, pages 5374 - 5379, ISSN: 0005011427 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6077857B2 (ja) | β−ヒドロキシ−β−メチル酪酸塩(HMB)の改善された投与方法 | |
US6207714B1 (en) | Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid | |
JP6619882B2 (ja) | D−プシコースを利用した脂質の吸収抑制および/または排出促進方法 | |
Tóth et al. | Treatment of rectal cancer with the paleolithic ketogenic diet: a 24-months follow-up | |
JP5680499B2 (ja) | 糖代謝改善組成物 | |
EP1397148B1 (en) | Chromium/biotin treatment of dyslipidemia | |
JP6313300B2 (ja) | 化合物ならびに食欲制御およびインスリン感受性に対するそれらの効果 | |
US20120116069A1 (en) | Glucose metabolism-improving agent and glucose metabolism-improving composition | |
Wilson et al. | Updates in nutrition management of cystic fibrosis in the highly effective modulator era | |
JP2020132588A (ja) | 血中pcsk9濃度上昇抑制用組成物 | |
WO2007091623A1 (ja) | メグリチニド類を含有する肝臓線維化予防用医薬組成物 | |
JP4838894B2 (ja) | 糖代謝改善剤 | |
JP2010059084A (ja) | 機能性食品及び医薬 | |
JP6391959B2 (ja) | 非アルコール性脂肪性肝炎の改善剤および改善用栄養組成物 | |
EP2067478A1 (en) | Agent for prevention or treatment of blood glucose level elevation | |
JP6112767B2 (ja) | 血液中の尿酸値を低下させるための組成物 | |
Kaur et al. | Can thyalakoids replace bariatric surgery for long term maintenance of weight loss in obesity giving a more physiological approach | |
EP1964558A1 (en) | Pharmaceutical compositions containing intestinal lipase inhibiting substances combined with a chromium dinicotinate o-coordinated complex for use in the treatment and control of obesity and overweight | |
Trandafir et al. | Management of dyslipidemia in childhood may prevent cardiovascular events in adults | |
JP2009511435A (ja) | 高脂血症の予防および治療のためのポリキトサミンとフィブレートの組み合わせ | |
JP2016153384A (ja) | ウロプラキン発現促進剤 | |
WO2006085523A1 (ja) | 血糖値上昇抑制用組成物 | |
Buchman | Nutrition in Inflammatory Bowel Disease | |
Pinsawas et al. | Asian Low-Carbohydrate Diet with Increased Whole Egg Consumption Improves Metabolic Outcomes in Metabolic Syndrome: A 52-Week Intervention Study | |
Buchman | Nutrition in Inflammatory Bowel Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230515 |